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ABSTRACT
Growth factor withdrawal inhibits cell cycle progres-
sion by stimulating expression of growth-arresting
genes through the activation of Forkhead box O
transcription factors such as FOXO3a, which binds
to the FHRE-responsive elements of a number of
target genes such as PUMA and GADD45a.
Following exposure of cells to growth factors
FOXO3a-mediatedtranscriptionisrapidlyrepressed.
We determined that repression correlates with acti-
vation of PI3K/AKT pathway leading to FOXO3a
phosphorylation and release of FOXO3a protein
from PUMA and GADD45a chromatin. We show
here that Myc significantly and selectively contrib-
utes to repression of FOXO-mediated expression of
PUMA and GADD45a. We found that in Myc deprived
cells inhibition of PUMA and GADD45a following
serum stimulation is impaired and that Myc does
not interfere with p53 induction of PUMA transcrip-
tion. We observed that following activation, Myc is
rapidly recruited to PUMA and GADD45a chromatin,
with a concomitant switch in promoter occupancy
from FOXO3a to Myc. Myc recruitment stimulates
deacetylation of Histone H3 and H4 and methylation
of lysine 9 in H3 (H3K9me2) on both PUMA and
GADD45 chromatin. These data highlight a Myc role
on cell growth by selectively inhibiting FOXO3a
induced transcription of PUMA and GADD45.
INTRODUCTION
FOXO transcription factors, through direct binding to the
cognate FHRE sites, direct expression of gene targets
governing cell cycle arrest, apoptosis, metabolism, differ-
entiation and oxidative defense. FOXO factors are regu-
lated through the phosphatidylinositol 3-kinase (PI3-K)
pathway. In the absence of growth factors, FOXOs are
localized to the nucleous and transcriptionally active
(1–3). Activation of AKT in response to growth factor
stimulation induces phosphorylation of FOXOs at three
highly conserved serine and threonine residues (2).
Because the PI3K-AKT axis is activated in virtually all
human cancers, FOXO proteins result frequently inactiv-
ated in cancer cells (4) and murine genetic studies provided
formal proof of the role of FOXOs in tumor suppression
(5,6). Constitutive FOXO3a activation results in the re-
pression of Myc target genes (6–8), suppression of Myc-
driven lymphomagenesis and activation of cell cycle arrest
and apopotsis in human renal cell carcinoma (6,9).
FOXO-mediated inhibition of Myc-target genes appears
to operate through induction of Mxi1-SRa and mir-145
(7,8). It has been suggested that FOXO3a and Myc might
co-regulate a common set of targets through their recruit-
ment to the respective cognate binding sites present on the
same sequences. Accordingly, there is a signiﬁcant overlap
between FOXO3a and Myc targets including growth-
promoting factors CyclinD2, CDK4, CyclinE2 (7)
and growth-arrest factors such as PUMA (10), p27kip1
(11–14) and GADD45a (15,16) suggesting that FOXO3a
and Myc might reciprocally regulate a common set of genes.
Here, we evaluate if Myc can interfere with FOXO3a-
dependent transcription of two targets, the proapoptotic
BBC3/PUMA (10) and the DNA damage-responsive
GADD45a (15). Using a conditional Myc expression sys-
tem, we determined that in response to serum withdrawal,
PUMA and GADD45 expression is upregulated by
FOXO3a-dependent activation. Following cell growth
stimulation and Myc activation, we found that Myc is
rapidly recruited to PUMA and GADD45a chromatin,
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FOXO3a to Myc. Myc recruitment signiﬁcantly and se-
lectively contributes to repression of FOXO-mediated ex-
pression of PUMA and GADD45a and its presence on
both PUMA and GADD45 chromatin correlates with in-
duction of histone repressive marks such as deacetylation
of Histone H3 and H4 and methylation of lysine 9 in H3
(H3K9me2) at these targets.
MATERIALS AND METHODS
Cell culture and drugs
RAT1 cells expressing a 4-hydroxytamoxifen (OHT)-indu-
cible MycER chimera (17), RAT1 and RAT-Myc
 /  cells
were cultured in DMEM medium supplemented with 10%
fetal calf serum. Cells were made quiescent by contact in-
hibition followed by serum removal for 2 days. To induce
entry into the cycle, synchronized growth-arrested cells
were treated with OHT (1mM) alone or OHT plus
serum or serum alone as indicated in the text and har-
vested at the indicated times. The AKT-inhibitor
LY294002 (10mM) was added in the media where
indicated. mRNA expression was quantiﬁed by qRT–
PCR (see below) and compared to quiescent cells.
mRNA levels were normalized to b-glucuronidase
(GUS) mRNA levels (18,19). Growing RAT-MycER
cells were treated with OHT for Myc induction (Myc)
for 4h. OHT-treated and control-untreated cells were
incubated with CPT (12mM for 4h) or Nutlin-3 (10mM
for 4h) and then PUMA and/or GADD45a mRNA levels
were quantiﬁed by qPCR as described below.
Transfections and siRNA
To carry out transient transfection experiments in RAT1
and RAT-MycER cells (19), we used MicroPoRATor
Digital Bio Technology, a pipette-type electroporation.
Indicated plasmids, DNAs or siRNA were introduced
into each 3 10
6 dissociated cells in 100ml volume accord-
ing to manufacturer’s instructions. Pulse width was deter-
mined according to applied voltages: 1400V, 30ms, 1pulse.
Electroporated cells were then seeded into 100-mm culture
dishes containing 5ml of culture media. After 5h of recov-
ery, the cells were serum deprived for 48h. For siRNA
treatments, ON-TARGETplus SMARTpool (L-003282-
00-0005) Myc; and ON-TARGETplus Non-targeting
pool (D-001810-10-5) were obtained from Dharmacon.
An amount of 100nM, ﬁnal concentration of the pools,
was used for each transfection. Expression of proteins was
determined by western blot. In transfection experiments,
RAT-MycER cells were transfected with the 3mgo f
FOXO3a-TM vector expressing a constitutively active
FOXO3a by electroporation as described (19) after 5h
of recovery, the cells were serum deprived for 48h and
mRNA levels were evaluated 1 and 4h after treatment
with serum and OHT.
mRNA quantiﬁcation by qPCR
cDNA was prepared from total RNA with the Quantitect
Reverse Transcription Kit (Qiagen) according to
manufactory instructions. Each sample was assayed in
triplicate. Oligoprimers are described in Supplementary
Data. The qPCR data were normalized to the expression
of the housekeeping b-glucuronidase (GUS) gene and
after normalization the data were presented as fold
change relative to the 0 point.
Quantitative chromatin immunoprecipitation
Quantitative chromatin immunoprecipitation (qChIP) ex-
periments were performed essentially as described (18,19).
For qPCR, 3ml out of 150ml of immunoprecipitated DNA
was used with primers described in Supplementary Data.
ACHR promoter amplicon was used as negative control
in all experiments. Normal serum and input DNA values
were used to subtract/normalize the values from qChIP
samples by using: % Input=2
DCt 3; DCt=Ct(input)-
Ct(cIP) (18,19). qRT–PCR and qChIP data are presented
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Figure 1. Myc inhibits FOXO3a-dependent transcription.
Asynchronous RAT-MycER growing cells (Gr) were serum deprived
for 2 days (0) and then treated with serum and OHT for 4h.
(A) Protein expression is shown in immunoblots of whole-cell extracts
with anti-PUMA, anti-GADD45, anti-Phospho-FOXO3a,
anti-FOXO3a and actin for loading control. (B) mRNA expression
levels of PUMA and GADD45 were quantiﬁed by qRT–PCR in asyn-
chronous RAT-MycER growing cells (Gr), quiescent (0) and after 1
and 4h of treatment with serum and OHT. mRNA levels were
normalized to b-glucuronidase (GUS) mRNA levels. All values repre-
sent the average of at least three independent experiments. Error bars
indicate SD. (C) RAT-MycER cells were transfected with the
FOXO3a-TM vector expressing a constitutively active FOXO3a by
electroporation as described; after 5h of recovery, the cells were
serum deprived for 48h and mRNA levels were evaluated 1 and 4h
after Myc induction in the presence of serum +OHT. The
AKT-inhibitor LY294002 (10mM) was added to the media where
indicated. mRNA expression was quantiﬁed by qRT–PCR and
compared to quiescent cells. mRNA levels were normalized to
b-glucuronidase (GUS) mRNA levels. All values represent the
average SD (n=3). Error bars are standard error of the mean.
*P<0 05, **P<0 01.
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Figure 2. Myc knockdown prevents repression of FOXO3a targets. (A) Serum deprived RAT-MycER cells (0) were treated for 4h with OHT
+
serum. Myc expression was inhibited with speciﬁc siRNA (siMyc) and siRNA non-targeting (siCtl) was used as scrambled RNAs. PUMA, GADD45
and Ncl mRNAs expression levels were quantiﬁed by qRT–PCR. Error bars indicate SD (n=3). Error bars are standard error of the mean.
*P<0 05. The efﬁciency of Myc silencing by siRNA treatments measured by qRT–PCR and by immunoblot is shown on the right. (B) Quiescent
RAT-MycER cells were stimulated with OHT+serum (black square), with OHT alone (empty circle) or with serum alone (black triangles) and
expression levels of PUMA and GADD45 were quantiﬁed by reverse transcription and real-time PCR at the indicated times after treatment; values
were compared to quiescent cells and presented as means of two independent experiments each analyzed by triplicate qRT–PCR. (C) RAT-Myc
 / 
cells as well as cells transfected with a Myc expression vector were serum deprived for 48h and PUMA and GADD45 mRNA levels were evaluated
by qRT–PCR 4h after serum induction. Values were compared to quiescent cells. (D) Serum deprived (2 days) RAT1 cells (O) were treated with
serum (10%) for 4h. Myc expression was inhibited with speciﬁc siRNA (siMyc) and siRNA non-targeting (siCtl) was used as scrambled RNAs.
PUMA and GADD45 mRNAs expression levels were quantiﬁed by qRT–PCR. Error bars indicate SD (n=3), *P<0 05. The efﬁciency of Myc
silencing by siRNA treatments measured by immunoblot is shown on the bottom.
9500 Nucleic Acids Research, 2011,Vol.39, No. 22as means of three at least independent biological ex-
periments each analyzed by triplicate ( SD). Statistical
signiﬁcance was determined using the matched pairs test.
RESULTS
Myc contributes to repression of PUMA and GADD45
expression following growth stimulation
To investigate how Myc could inﬂuence FOXO3a-
dependent transcription we used the RAT-MycER ﬁbro-
blast cell line (18) in which the inducible MycER protein is
activated upon treatment with tamoxifen (OHT). PUMA
and GADD45a expression was monitored in asynchron-
ous RAT-MycER cells, and in cells that were serum
deprived for 2 days and then treated with OHT/serum
for cell cycle reentry and Myc activation. As largely expected,
PUMA and GADD45a expression is upregulated in re-
sponse to growth factor deprivation, and addition of
serum inhibits their expression (Figure 1A and B). In the
absence of serum, the phosphoinositide 3-kinase PI3K/
AKT pathway is inactive and FOXO3a remains unphos-
phorylated into the nucleus where it activates target genes
(1,2). FOXO3a phosphorylation is inhibited by serum
withdrawal and phosphorylation is restored 4h after
serum addition (Figure 1A). Moreover, the presence of
the PI3-K inhibitor LY294002 or the overexpression of the
constitutively active FOXO3a-TM, prevents PUMA and
GADD45a repression by serum (Figure 1C). Collectively,
these data indicate that activation of FOXO3a in serum-
deprived RAT-MycER ﬁbroblasts stimulates the expres-
sion of growth-arrested genes PUMA and GADD45a;
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Figure 3. Myc, FOXO3a and Rpb1occupancy on PUMA and GADD45 chromatin. Asynchronous RAT-MycER growing cells (Gr) were serum
deprived for 2 days (00) and then treated with serum and OHT serum for Myc activation at the indicated times (300,6 0 0 and 2400). qChIP was
performed using antibodies recognizing FOXO3a (A), Myc (B) and Rpb1 (C). The amplicons used are reported in Supplementary Data. (D)
FOXO3a occupancy on PUMA and GADD45 chromatin in growing (Gr) starved (00) and serum treated (600 and 2400) RAT Myc
 /  cells.
ChIP-enriched DNA was quantiﬁed by real-time PCR analysis using amplicons reported in Supplementary Data. The values reported were calculated
as fold percentage of amount of immunoprecipitated DNA relative to that present in total input chromatin. All qChIP data are presented as mean of
at least three independent biological experiments each analyzed by triplicate SDs. ACHR promoter amplicon was used as negative control in all
experiments.
Nucleic Acids Research, 2011,Vol.39, No. 22 9501conversely, cell growth stimulation by serum is accom-
panied by repression of FOXO3a-dependent expression
of these negative regulators of cell proliferation.
Because RAT-MycER cells express a conditional
activated Myc protein, we sought to determine the relative
contribution of Myc in the repression of FOXO3a target
genes. We ﬁnd that silencing of Myc with speciﬁc siRNA
restores PUMA and GADD45a expression to levels com-
parable to that observed in serum-starved cells (Figure 2,
panel A). As control, Myc silencing strongly reduces the
expression of Nucleolin (NCL), a well-deﬁned target for
Myc activation (19). In serum-tarved cells, we did not
detect signiﬁcant differences on the relative levels of
mRNA in samples treated with siCtl or siMyc, suggesting
that in serum-starved cells, expression of both PUMA and
GADD45 is largely independent from Myc. To determine
the relative contribution of serum and Myc activation of
the repression of PUMA and GADD5a, we compared the
relative levels of expression in cells that were treated with
serum alone, OHT and serum+OHT treatments. We
found that Myc is able to repress FOXO3a-target genes
even in the absence of serum, although under these con-
ditions the kinetic of inhibition is slower (Figure 2B). On
the other hand, serum does not fully substitute for Myc in
the repression of PUMA and GADD45, because in
RAT-Myc
 /  cells serum addition does not fully repress
FOXO3a-targets (Figure 2C); however, a robust repres-
sion of PUMA and GADD45a mRNA levels were restored
in RAT-Myc
 /  in which a Myc expression vector has
been transfected (Figure 2C). To further investigate the
endogenous Myc activity in response to serum addition,
we monitored PUMA and GADD45a expression in RAT1
cells that were serum deprived for 2 days and then treated
with serum for cell cycle re-entry. In response to serum
addition expression of both PUMA and GADD45a was
inhibited, and most importantly silencing of endogenous
Myc with speciﬁc siRNA restores PUMA and GADD45a
expression (Figure 2D). Collectively, these results high-
light a crucial contributory role of Myc in the inhibition
of FOXO3a-dependent gene expression in response to
growth factor stimulation.
FOXO3a and Myc occupancy on PUMA and GADD45
chromatin is mutually exclusive
Previous works showed that Myc represses GADD45a
through binding to the proximal promoter sequences
(15,16), and several high afﬁnity E-box sites for Myc
binding have been mapped upstream the ATG site of
PUMA (20–23), although a direct proof of Myc-binding
to these putative E-boxes has not been documented.
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Figure 4. Histone modiﬁcations on PUMA chromatin following Myc activation. RAT-MycER serum starved cells (00) are compared to cells induced
with OHT and serum for Myc activation (600). qChIP was performed using speciﬁc antibodies recognizing H3K4me3, H3K4me2, H3K9me3,
H3K9me2, H3Ac and H4Ac as indicated. ChIP-enriched DNA was quantiﬁed by real-time PCR analysis using amplicons surrounding PUMA
transcription start site (TSS) and E-BoxII (Supplementary Data). The qChIP data are presented as in Figure 3 and ChIP-enriched DNA was
quantiﬁed as previously indicated.
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studies showed that PUMA contains high afﬁnity E-box
sites for Myc binding, suggesting that PUMA may repre-
sent a putative direct target of Myc. Moreover, clustering
Myc target genes on the basis of histone modiﬁcation
marks, the PUMA E-boxes are characterized by high
levels of histone methylation at H3K4me3, a pre-requisite
for Myc binding and at H3K9me2, which is generally con-
sidered a repressive mark (24,25).
To assess Myc and FOXO3a occupancy on FOXO3a-
targets (PUMA and GADD45) we carried out qChIP
analysis in RAT-MycER growing cells (Gr), serum de-
prived for 2 days (00) and treated for 600 and 2400 with
OHT/serum. First of all we determined that the PUMA
E-boxII is the highest afﬁnity Myc binding site and that
Myc is recruited on this site rather early (600) after induc-
tion (Supplementary Figure S1). Accordingly to the induc-
tion of expression of PUMA after serum withdrawal
(Figure 1, panels A and B), recruitment of FOXO3a on
the FHRE sequence is found in serum-starved cells (00)
(Figure 3A). As soon as Myc is recruited on E-BoxII chro-
matin, FOXO3a disappears on PUMA chromatin. Similar
results are obtained by exploring GADD45 FHRE and
TSS for Foxo3a and Myc occupancy (Figure 3B). These
results indicate that upon cell cycle re-entry and Myc ac-
tivation, there is a concomitant switch in promoter
occupancy from FOXO3a to Myc resulting in transcrip-
tional repression. Accordingly we also determined that the
large subunit of RNAPII, Rpb1 occupancy at the tran-
scription start sites of both PUMA and GADD45 is
sharply reduced 600 after Myc activation (Figure 3C). To
address the relevance of serum on the reciprocal inhibition
of binding to the chromatin of Myc and FOXO3a we
performed a qChIP analysis in the RAT Myc
 /  cells of
FOXO3a occupancy in starved and serum-induced cells.
As shown in Figure 3D, FOXO3a occupancy of the
PUMA and GADD45a FHRE chromatin after 600 and
2400 is slightly affected by serum addition compared to
the strong reduction of FOXO3a observed in the
presence of Myc, suggesting a causative role of Myc in
the repression of FOXO3a-dependnet transcription.
Myc induces H3K9 methylation and H3–H4
de-acetylation on FOXO3a-targets chromatin
Myc responsive regions on the genome are characterized
by speciﬁc histones marks (20–22). High afﬁnity Myc
binding sites are marked by tri-methylation of lysine 4 in
the histone H3 tail. Upon Myc binding, changes in the
methylation and acetylation levels of histones H3 and
H4 have been correlated to the Myc positive or negative
effects on transcription efﬁciency of its targets (26,27). We
have performed qChIP assays to analyze histones
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Figure 5. Histone modiﬁcations on GADD45 chromatin following Myc activation. RAT-MycER serum starved cells (00) are compared to cells
induced with OHT and serum for Myc activation (600). qChIP was performed using speciﬁc antibodies recognizing H3K4me3, H3K4me2, H3K9me3,
H3K9me2, H3Ac and H4Ac as indicated. ChIP-enriched DNA was quantiﬁed by real-time PCR analysis using amplicons (Supplementary Data)
surrounding the TSS ( 332) and FHRE (+23). The qChIP data are presented as described in Figure 3.
Nucleic Acids Research, 2011,Vol.39, No. 22 9503methylation and acetylation marks on PUMA TSS and
E-boxII sequences (Figure 4) and on GADD45 FHRE
and TSS sequences (Figure 5) following Myc binding.
We have focused our attention on the methylation
proﬁle of lysine 4 and 9 of histone H3 and on
pan-acetylation of histones H3 and H4. While
H3K4me3, H3K4me2 and H3K9me3 levels remain
largely unchanged, a robust increase of H3K9me2 is
found on PUMA TSS and E-BoxII upon treatment with
serum and MycER nuclear translocation by OHT treat-
ment (Figure 4). Concurrent with Myc binding, we also
detect a sharp reduction of H3- and H4-acetylated levels
on PUMA TSS and E-BoxII sequences (Figure 4). Similar
changes in chromatin modiﬁcations were found on the
chromatin of GADD45 gene (Figure 5).
However, the combined treatment of RAT-MycER cells
with OHT and serum does not allow to discriminate
between the effects of Myc activation and serum-induced
inactivation of FOXO3a. To deﬁne the relative contribu-
tion of Myc activation and serum, we carried out qChIP
assays in RAT1 cells that only express the endogenous
Myc analyzing histone modiﬁcations on GADD45 and
PUMA chromatin in serum starved versus serum-treated
cells. Comparing the ChIP data from RAT-MycER
(Figures 4 and 5) with RAT1 cells (Figure 6 and
Supplementary Figure S2) we ﬁnd, as consequence of
serum addiction to starved cells, a slower (4h versus 1h)
reduction of acetylated H3/H4Ac (Figure 6A and B) on
both PUMA and GADD45 chromatin (Supplementary
Figure S2), and increased levels of methylation of H3K9
(Figure 6C) in the RAT1 cells. Furthermore, to support
the relevant role of the endogenous Myc, we silenced Myc
expression in RAT1 cells and, as shown in Figure 6, panel
D, we ﬁnd that the levels of H3 and H4 acetylation are
largely unaffected in silenced cells, suggesting a causative
role of Myc in the H3/H4 reduction following serum
stimulation. To further support the role of Myc in the
loss of H3 and H4 acetylation, we have used RAT
Myc
 /  cells to analyze H3/H4Ac occupancy on
FOXO3a-targets. In this Myc null cell line, after 600 and
2400 of serum starvation, H3/H4Ac occupancy of the both
PUMA and GADD45 chromatin is largely unaffected,
consistent with a relevant role of Myc in the reduction
of H3- and H4-acetylated levels of both PUMA and
GADD45 (Figure 7A). Finally, inhibition of histone
deacetylases by TSA severely impairs Myc inhibitory
effect on PUMA and GADD45 expression, following
Myc induction (Figure 7B and C). These data indicate
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Figure 6. Myc is required for histone modiﬁcation of PUMA chromatin. Asynchronous RAT1 growing cells were serum-deprived for 2 days (00) and
then treated with serum (10%) and samples collected at the indicated times (300,6 0 0 and 2400) and qChIP was performed using speciﬁc antibodies
recognizing H3Ac, H4Ac and H3K9me2, as indicated in panels A, B and C. ChIP-enriched DNA was quantiﬁed by real-time PCR analysis using
amplicons surrounding PUMA, TSS and E-BoxII. The qChIP data are presented as in Figure 3. (D and E) Serum deprived (2 days) RAT1 cells (O)
were treated with serum (10%) for 4h. Myc expression was inhibited with speciﬁc siRNA (siMyc) and siRNA non-targeting (siCtl) was used as
scrambled RNAs. qChIP was performed using antibody recognizing H4Ac, and ChIP-enriched DNA was quantiﬁed by real-time PCR analysis using
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9504 Nucleic Acids Research, 2011,Vol.39, No. 22that Myc binding on PUMA and GADD45 regulatory
regions correlates with increased methylation of H3K9
and with deacetylation of H3/H4.
Myc does not interfere with p53-mediated
activation of PUMA
We sought to determine the speciﬁcity of Myc repressive
effect on PUMA transcription independently from
FOXO3a activation. PUMA expression following DNA
damage is stimulated by p53 binding through consensus
p53-responsive elements located within its promoter
(23 and references therein). To determine whether Myc
might suppress p53-mediated activation of PUMA, we
analyzed the effect of Myc in the presence of active p53.
p53 is activated by the DNA damaging compound
Camptothecin (CPT) or by Nutlin-3, which disrupting
p53-MDM2 interaction releases the active form of p53
(28). Asynchronous RAT-MycER growing cells were
treated with CPT or Nutlin-3 for 4h prior to Myc activa-
tion and PUMA mRNA levels were quantiﬁed by qRT–
PCR (Figure 8A). Both CPT and Nutlin-3 treatments
activate PUMA expression in the presence or absence of
Myc. Next, we performed qChIP assays to analyze the
occupancy of Myc and Rpb1 on PUMA regulatory
regions following p53 activation by CPT and Nutlin-3.
Figure 8B demonstrates that in condition in which CPT
and Nutlin-3 activate PUMA, E-box occupancy by Myc
is unaffected. Accordingly, TSS occupancy by Rpb1 in
cells treated for p53 activation (CPT or Nutlin-3)
remains unchanged after Myc activation (Figure 8C).
These data demonstrate that Myc binding does not inter-
fere with p53-mediated activation of PUMA and indi-
cate that Myc is not a global repressor of PUMA
expression.
DISCUSSION
In this report, we show that Myc and the PI3/AKT
pathway cooperate in the repression of FOXO3a-
dependent gene activation. Compelling evidences strongly
suggest that Myc and PI3/AKT/FOXO3a pathways co-
operate in the activation of Myc target genes, and abro-
gation of FOXO function promotes focus formation by
Myc in vitro, and dramatically accelerates Myc-driven
lymphomagenesis in vivo (7–9). Recent studies provided
evidences that FOXO-mediated inhibition of Myc func-
tions operates via suppression of Myc through upregula-
tion of the Myc antagonists, Mxi1-SRa and mir-145 (6).
The ﬁndings reported here suggest that the synergy
between Myc and PI3/AKT/FOXO3a pathway has an
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Nucleic Acids Research, 2011,Vol.39, No. 22 9505important role not only in the activation of multiple Myc
target genes involved in cell proliferation, but also in re-
pression of FOXO3a targets involved in anti-proliferative
function such as PUMA and GADD45a. Reciprocal
control by Myc and FOXO3a has been also described in
the regulation of p27Kip1transcription (11–13), and it has
been suggested that Myc inhibits p27 transcription via
physical association with FOXO3a (14). The presence of
Myc on PUMA or GADD45a chromatin in the absence
of FOXO3a, suggests that Myc recruitment does not
rely on a physical FOXO3a/Myc interaction. Moreover,
several attempts to detect interaction between Myc and
FOXO3a using both endogenous and over-expressed
proteins failed (data not shown), and we conclude that
the divergent FOXO3a and Myc-mediated regulation of
targets genes requires the recruitment of these factors in an
independent and mutually exclusive manner. Indeed, there
is a signiﬁcant overlap between FOXO3a and Myc targets
including growth-promoting factors CyclinD2, CDK4
CyclinE2 and growth-arrest factors such as PUMA,
p27kip1 and GADD45a. It is highly suggestive that the
opposite activity of FOXO3a and Myc proteins on
common targets will profoundly affect the proliferation
of normal and tumor cells (Figure 8D).
Our ﬁndings provide a mechanistic model for under-
standing the cooperation of Myc and PI3/AKT-signaling
in repression of FOXO3a-dependent activation. First, in
response to serum withdrawal PUMA and GADD45a are
activated at transcriptional level and binding of active
FOXO3a to the cognate FHRE sites is largely responsible
for this effect. Serum external growth factors induce acti-
vation of the survival kinase AKT leading to phosphoryl-
ation of FOXO3a. However, AKT activation is not fully
sufﬁcient to repress FOXO-3a-dependent transcription.
Myc binding to the FOXO3a targets further contributes
to repression by establishing the repressive chromatin
marks characterized by deacetylation of H3/H4 histones
and increased levels of H4K9me2.
It has been recently reported that Myc-mediated repres-
sion of GADD153 and Id2 genes involves direct Myc
binding to the E-box and a process that involves histone
deacetylation (29). The ﬁndings reported here strongly
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9506 Nucleic Acids Research, 2011,Vol.39, No. 22suggest that Myc-mediated repression of FOXO3a-
dependent transcription correlates with induction of
repressive epigenetic changes of target genes.
Following Myc activation, FOXO3a-mediated tran-
scription is shut off and concurrently a robust increase
of H3K9me2 (likely due to H3K9me1 methylation) and
de-acetylation of H3 and H4 occurs on FOXO3a targets.
Further investigations will be necessary to identify the H3/
H4 de-acetylase and H3K9 methylase responsible of Myc
mediated changes of FOXO3a target genes chromatin.
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